Patents by Inventor Kim Suzanne Midwood

Kim Suzanne Midwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-tenascin C antibodies and uses thereof
    Patent number: 11814426
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: November 14, 2023
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • Human antibodies and binding fragments thereof to tenascin
    Patent number: 11332520
    Abstract: The present disclosure relates to antibodies and binding fragments to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to compositions comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and/or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making the antibodies.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 17, 2022
    Assignee: STERLING IP LIMITED
    Inventors: Patrick Hextall, Kim Suzanne Midwood, Eric Culbert
  • ANTI-TENASCIN C ANTIBODIES AND USES THEREOF
    Publication number: 20210355201
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Application
    Filed: April 13, 2021
    Publication date: November 18, 2021
    Inventors: Kim Suzanne MIDWOOD, Philip Antony BLAND-WARD, Nigel BURNS, Patrick John HEXTALL, Susan Rebecca AUNGIER
  • Anti-tenascin C antibodies and uses thereof
    Patent number: 11008384
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 18, 2021
    Assignee: STERLING IP LIMITED
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • BIOLOGICAL MATERIALS AND USES THEREOF
    Publication number: 20200362024
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents.
    Type: Application
    Filed: April 6, 2020
    Publication date: November 19, 2020
    Inventors: Kim Suzanne Midwood, Brian Maurice John Foxwell
  • BIOLOGICAL MATERIALS AND THERAPEUTIC USES THEREOF
    Publication number: 20200255825
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of citrullinated tenascin-C. There is also provided methods of identifying agents modulating citrullinated tenascin-C and chronic inflammation. There are also provided therapeutic uses of such agents.
    Type: Application
    Filed: September 10, 2019
    Publication date: August 13, 2020
    Inventors: Kim Suzanne MIDWOOD, Patrick John VENABLES
  • HUMAN ANTIBODIES AND BINDING FRAGMENTS THEREOF TO TENASCIN
    Publication number: 20200223910
    Abstract: The present disclosure relates to antibodies and binding fragments to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to compositions comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and/or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making the antibodies.
    Type: Application
    Filed: February 10, 2017
    Publication date: July 16, 2020
    Inventors: Patrick HEXTALL, Kim Suzanne MIDWOOD, Eric CULBERT
  • ANTI-TENASCIN C ANTIBODIES AND USES THEREOF
    Publication number: 20200190177
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 18, 2020
    Inventors: Kim Suzanne MIDWOOD, Philip Antony BLAND-WARD, Nigel BURNS, Patrick John HEXTALL, Susan Rebecca AUNGIER
  • Treatment for Dupuytren's disease
    Patent number: 10669334
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 2, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Anti-tenascin C antibodies and uses thereof
    Patent number: 10533047
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: January 14, 2020
    Assignee: NASCIENT LIMITED
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • TREATMENT FOR DUPUYTREN'S DISEASE
    Publication number: 20190322733
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 24, 2019
    Applicant: Oxford University Innovation Limited
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Treatment for dupuytren's disease
    Patent number: 10273296
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 30, 2019
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • ANTI-TENASCIN C ANTIBODIES AND USES THEREOF
    Publication number: 20190055306
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • BIOLOGICAL MATERIALS AND USES THEREOF
    Publication number: 20190040122
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 7, 2019
    Inventors: Kim Suzanne Midwood, Brian Maurice John Foxwell
  • Anti-tenascin C antibodies and uses thereof
    Patent number: 10093723
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 9, 2018
    Assignee: Nascient Limited
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • Biomarker and uses thereof
    Patent number: 10088479
    Abstract: The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: October 2, 2018
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Kim Suzanne Midwood, Patrick John Venables
  • Biological Materials and Uses Thereof
    Publication number: 20180022792
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C. There is also provided methods of identifying agents modulating tenascin-C and chronic inflammation. There are also provided uses of such agents.
    Type: Application
    Filed: July 22, 2015
    Publication date: January 25, 2018
    Inventors: Kim Suzanne Midwood, Brian Maurice John Foxwell
  • ANTI-TENASCIN C ANTIBODIES AND USES THEREOF
    Publication number: 20170306005
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Application
    Filed: August 7, 2015
    Publication date: October 26, 2017
    Inventors: Kim Suzanne MIDWOOD, Philip Antony BLAND-WARD, Nigel BURNS, Patrick John HEXTALL, Susan Rebecca AUNGIER
  • BIOLOGICAL MATERIALS AND THERAPEUTIC USES THEREOF
    Publication number: 20170009228
    Abstract: There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of citrullinated tenascin-C. There is also provided methods of identifying agents modulating citrullinated tenascin-C and chronic inflammation. There are also provided therapeutic uses of such agents.
    Type: Application
    Filed: January 13, 2015
    Publication date: January 12, 2017
    Inventors: Kim Suzanne MIDWOOD, Patrick John VENABLES
  • BIOMARKER AND USES THEREOF
    Publication number: 20160327556
    Abstract: The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 10, 2016
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Kim Suzanne Midwood, Patrick John Venables